Aptevo Therapeutics Inc., of Seattle, said it amended the terms of a credit agreement initially executed with Midcap Financial Trust in August last year. Read More

Affigen LLC, of St. Louis, and CCRM, a Canadian not-for-profit organization funded by the Canadian government, the Province of Ontario and leading academic and industry partners to support regenerative medicines and associated enabling technologies, said they partnered to create and commercialize a closed platform for the production of individualized, tumor-identifying therapeutics for the treatment of a range of currently incurable cancers. Read More

Prothena Corp. plc, of Dublin, reported results from a phase Ib multiple ascending dose trial testing PRX003 in 33 patients with psoriasis. PRX003, a monoclonal antibody targeting CD146 that's expressed on T helper 17 cells (Th17), didn't produce meaningful clinical benefit as measured by responses in the Psoriasis Area and Severity Index 75. Read More

The epithelial to mesenchymal transition (EMT) is a dedifferentiation process that occurs in tumor cells as they become more invasive. It has also been implicated as an important process in dedifferentiation that occurs during the generation of induced pluripotent stem cells (iPSCs). Read More

A year after its seed financing, Peptilogics Inc. closed a $5.5 million series A to advance its engineered cationic antibiotic peptide, or ECAP, platform to ply multidrug-resistant (MDR) bacterial infections. The ECAP mechanism enables direct targeting and disruption of bacterial membranes without lysing, causing rapid death of both dormant and growing bacterial cells. Read More

Although trading nipped shares of United Therapeutics Corp. when the news broke, few onlookers likely felt shock when the data monitoring committee (DMC) decreed earlier this month that the company keep going with its Freedom-Ev trial testing vasodilator Orenitram (treprostinil extended-release tablets). Read More

In findings with implications for both drug discovery and cell fate, researchers have developed a method to map regulatory elements called enhancers to their target genes. Read More

BOSTON – At last week's Biopharm America meeting, Astellas Pharma Inc.'s Salim Mujais sat down with BioWorld for a high-level look at the Tokyo-based firm's efforts in therapeutic areas outside of cancer. Read More

LONDON – And the votes are in: Amsterdam is the city most favored by the EMA's 890 staff as the new home for the agency when it relocates from London after Brexit. Read More

Positive new pivotal data has shown that ZX-008, Zogenix Inc.'s re-imagining of a key component of the ill-fated obesity drug Fen-Phen, can significantly reduce seizure frequency in children with the rare genetic epilepsy, Dravet syndrome. Read More